Min Shen

12.8k citations

162 papers · 7.2k indexed · 3 hit papers · h-index 42

Computational Theory and Mathematics top 0.2%
- Computational Drug Discovery Methods 26
Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism 21
Infectious Diseases top 1%
- SARS-CoV-2 and COVID-19 Research 16
- COVID-19 Clinical Research Studies 10
Molecular Biology top 2%
- Biochemical and Molecular Research 11
- Ubiquitin and proteasome pathways 8
Oncology top 5%
- Cancer-related Molecular Pathways 8
Biochemistry
- Amino Acid Enzymes and Metabolism 8

Co-authors: Anton Simeonov Douglas S. Auld Matthew D. Hall Alexander Tropsha Alexander Golbraikh Craig J. Thomas Matthew B. Boxer Kyle R. Brimacombe
Cited by: Computational Theory and Mathematics Cancer Research Infectious Diseases
Journals: Journal of Medicinal Chemistry (9 papers)Bioorganic & Medicinal Chemistry Letters (8 papers)ACS Pharmacology & Translational Science (8 papers)
Partner nations: United States China Germany

In The Last Decade

Min Shen

156 papers receiving 7.0k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Min Shen

Since Specialization

Citations

This map shows the geographic impact of Min Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min Shen more than expected).

Fields of papers citing papers by Min Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Min Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min Shen. The network helps show where Min Shen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Min Shen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Min Shen Line = papers co-authored together Min Shen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Limitations of acyclovir and identification of potent HSV antivirals using 3D bioprinted human skin equivalents Nature Communications ·S. Tori Ellison,畅征,大木順子,高橋伸,Kuniyoshi,Zina Itkin,Min Shen,A.M. Jones,S. Bourg,Lawrence Corey,Anna Wald,Christine Johnston,Youyi Fong,Marc Ferrer,Jia Zhu	2025	1
2	Glycolysis in human cancers: Emphasis circRNA/glycolysis axis and nanoparticles in glycolysis regulation in cancer therapy Environmental Research ·Ali G. Alkhathami,Iliana,総務省情報通信政策局総合政策課,Annie Scuilli Boyd,Mohammed Abed Jawad,В. И. Сергиенко,Sun Jung Kwan,Abbas F. Almulla,Min Shen	2023	11
3	Multimodal action of KRP203 on phosphoinositide kinases in vitro and in cells Biochemical and Biophysical Research Communications ·Yoshiki Ikeda,Mindy I. Davis,Kazutaka Sumita,Yu-Xiang Zheng,Satoshi Kofuji,Mika Sasaki,Yoshihisa Hirota,Rajan Pragani,Min Shen,Matthew B. Boxer,Koh Takeuchi,Toshiya Senda,Anton Simeonov,Atsuo T. Sasaki	2023	1
4	Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms Cancers ·Renée McCauley,Luigi Scotto,Thomas Litman,Srinath Mote,Hu Zhu,Min Shen,Robert W. Robey,Matthew D. Hall,Tito Fojo,Susan E. Bates	2023	1
5	Discovery of Novel Small-Molecule Scaffolds for the Inhibition and Activation of WIP1 Phosphatase from a RapidFire Mass Spectrometry High-Throughput Screen ACS Pharmacology & Translational Science ·Jenna Forster,Yuhong Fang,Dingyin Tao,Hui-biao,Hongmao Sun,Veronica Sanchez-Ortega,Karavadhi Surendra,Kelly Lane,Zhendan Shi,Olga Vasalatiy,Christopher A. LeClair,Н.В. Терешко,Min Shen,Samarjit Patnaik,Ettore Appella,Nathan P. Coussens,Matthew D. Hall,Daniel H. Appella	2022	7
6	Virtual Screening for the Discovery of Microbiome β-Glucuronidase Inhibitors to Alleviate Cancer Drug Toxicity Journal of Chemical Information and Modeling ·Anup P. Challa,Xin Hu,Yaqin Zhang,Jeffrey L. Hymes,Bret D. Wallace,Karavadhi Surendra,Hongmao Sun,Samarjit Patnaik,Matthew D. Hall,Min Shen	2022	9
7	GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling Molecular Cancer Therapeutics ·Jiajia Pan,Nan Li,Alex Renn,Hu Zhu,Lu Chen,Min Shen,Matthew D. Hall,Min Qian,Ira Pastan,Mitchell Ho	2022	8
8	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments Briefings in Bioinformatics ·Ziaurrehman Tanoli,Jehad Aldahdooh,فاطمه ابراهیمی فینی,Yinyin Wang,Jessica Minahan,Maddalena Fratelli,Cheng Fang,Marián Hajdúch,Florence Biétrix,Philip Gribbon,Andrea Zaliani,Matthew D. Hall,Min Shen,Kyle R. Brimacombe,Evgeny Kulesskiy,Jani Saarela,Krister Wennerberg,Markus Vähä‐Koskela,Jing Tang	2021	8
9	The Natural Product β-Escin Targets Cancer and Stromal Cells of the Tumor Microenvironment to Inhibit Ovarian Cancer Metastasis Cancers ·Hilary A. Kenny,Peter C. Hart,Werner Schlagner,Madhu Lal,Min Shen,Shiho OGATA,Yen‐Ju Chen,Niklas Graßl,Santa Marina Rodríguez Loreto,Bikash R. Pattnaik,Karen M. Watters,Manish S. Patankar,Marc Ferrer,Ernst Lengyel	2021	20
10	Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants ACS Pharmacology & Translational Science ·Sankalp Jain,Lukáš Zákora,Bolormaa Baljinnyam,Talal Asad,Quinlin Hanson,Wei Zhu,Miao Xu,Catherine Z. Chen,Wei Zheng,Xin Hu,Min Shen,Ganesha Rai,Matthew D. Hall,Anton Simeonov,Alexey Zakharov	2021	10
11	A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib) Clinical Cancer Research ·Chandrayee Ghosh,Suresh Kumar,Yevgeniya Kushchayeva,Kelli Gaskins,Myriem Boufraqech,Darmood Wei,Sudheer Kumar Gara,Lisa Zhang,Yaqin Zhang,Min Shen,Sanjit Mukherjee,Electron Kebebew	2020	18
12	Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis Molecular Cancer Therapeutics ·Hilary A. Kenny,Madhu Lal‐Nag,Min Shen,Shiho OGATA,Dominik A. Nahotko,Kristen Wroblewski,Sarah Fazal,Siquan Chen,Chun-Yi Chiang,Yen‐Ju Chen,Kyle R. Brimacombe,Juan Marugán,Marc Ferrer,Ernst Lengyel	2019	22
13	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein Molecular Pharmacology ·Tobie D. Lee,Olivia W. Lee,Kyle R. Brimacombe,Lu Chen,Rajarshi Guha,Sabrina Lusvarghi,椛沢宏之,Carleen Klumpp‐Thomas,Robert W. Robey,Suresh V. Ambudkar,Min Shen,Michael M. Gottesman,Matthew D. Hall	2019	22
14	Structure–Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors ACS Medicinal Chemistry Letters ·Theresa Manz,Jing Ma,Adam Yasgar,Matthew D. Hall,Mindy I. Davis,Hyuk‐Soo Seo,Seema Redekar,Scott B. Ficarro,Hyeseok Shim,Jarrod A. Marto,Sirano Dhe‐Paganon,Atsuo T. Sasaki,Matthew B. Boxer,Anton Simeonov,Lewis C. Cantley,Min Shen,Tinghu Zhang,Fleur M. Ferguson,Nathanael S. Gray	2019	13
15	Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma Clinical Cancer Research ·Kei Satoh,Lisa Zhang,Yaqin Zhang,Raju Chelluri,Myriem Boufraqech,Naris Nilubol,Dhaval Patel,Min Shen,Electron Kebebew	2016	77
16	Diaphorase Coupling Protocols for Red-Shifting Dehydrogenase Assays Assay and Drug Development Technologies ·Mindy I. Davis,Min Shen,Anton Simeonov,Matthew D. Hall	2016	16
17	Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia Cancer Research ·Warren Fiskus,Nakhle S. Saba,Min Shen,Mondana Ghias,Jinyun Liu,Soumyasri Das Gupta,Lata Chauhan,Rekha Rao,Sumedha Gunewardena,F. Ferrere,Christopher P. Austin,Kami J. Maddocks,John C. Byrd,Ari Melnick,Peng Huang,Adrian Wiestner,Kapil N. Bhalla	2014	198
18	Structure-Guided Design of a High-Affinity Platelet Integrin α _IIb β ₃ Receptor Antagonist That Disrupts Mg ²⁺ Binding to the MIDAS Science Translational Medicine ·Jieqing Zhu,Won Suk Choi,Sarah Hirsch,Ana Negri,Jianghai Zhu,Мария Андреевна Понятая,Jihong Li,Min Shen,Wenwei Huang,Daniel W. Bougie,Mark Rasmussen,Richard H. Aster,Craig J. Thomas,Marta Filizola,Timothy A. Springer,Barry S. Coller	2012	73
19	Toward Improved Therapy for Classic Galactosemia Europe PMC (PubMed Central) ·Matthew B. Boxer,Min Shen,Cordelle Tanega,Manshu Tang,Kent Lai,Douglas S. Auld	2011	2
20	Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124 Proceedings of the National Academy of Sciences ·Douglas S. Auld,Scott Lovell,Natasha Thorne,Wendy Lea,David J. Maloney,Min Shen,Ganesha Rai,K.P. Battaile,Craig J. Thomas,Anton Simeonov,Robert P. Hanzlik,James Inglese	2010	148

About Min Shen

Min Shen is a scholar working on Cancer Research, Computational Theory and Mathematics and Biochemistry, having authored 162 papers that have together received 7.2k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (26 papers), Cancer, Hypoxia, and Metabolism (21 papers), SARS-CoV-2 and COVID-19 Research (16 papers), Biochemical and Molecular Research (11 papers), COVID-19 Clinical Research Studies (10 papers), Ubiquitin and proteasome pathways (8 papers), Cancer-related Molecular Pathways (8 papers) and Amino Acid Enzymes and Metabolism (8 papers). The work is most often cited by research in Computational Theory and Mathematics (1.5k citations), Cancer Research (1.2k citations) and Infectious Diseases (1.1k citations). Min Shen has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Anton Simeonov, Douglas S. Auld, Matthew D. Hall, Alexander Tropsha, Alexander Golbraikh, Craig J. Thomas, Matthew B. Boxer, Kyle R. Brimacombe, Richard T. Eastman and Samarjit Patnaik. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, ACS Pharmacology & Translational Science, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact